The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
Open accessAbstract
BACKGROUND: Trastuzumab is part of the standard treatment for patients with human epidermal growth factor receptor 2 (HER‐2)‐positive breast cancer, but not all patients respond to trastuzumab. Altered microRNA (miR) expression levels in cancer cells have been correlated with prognosis and response to chemotherapy. The authors of this report hypothesized that altered miR expression levels in plasma are associated with sensitivity to trastuzumab in patients with HER‐2 positive breast cancer. METHODS: Quantitative reverse transcriptase‐polymerase chain reaction was used to analyze plasma samples, including samples from patients with breast cancer who were enrolled in a clinical trial of neoadjuvant trastuzumab‐based chemotherapy. Expression levels of miR‐210, miR‐21, miR‐29a, and miR‐126 were analyzed according to the type of response (pathologic complete response [n = 18] vs residual disease [n = 11]). MicroRNA expression levels also were compared in trastuzumab‐sensitive and trastuzumab‐resistant breast cancer cells derived from BT474 cells and in an independent set of preoperative plasma samples (n = 39) and postoperative plasma samples (n = 30) from 43 breast cancer patients who did not receive any treatment. RESULTS: At baseline before patients received neoadjuvant chemotherapy combined with trastuzumab, circulating miR‐210 levels were significantly higher in those who had residual disease than in those who achieved a pathologic complete response (P = .0359). The mean expression ratio for miR‐210 was significantly higher in trastuzumab‐resistant BT474 cells, and miR‐210 expression was significantly higher before surgery than after surgery (P = .0297) and in patients whose cancer metastasized to the lymph nodes (P = .0030). CONCLUSIONS: Circulating miR‐210 levels were associated with trastuzumab sensitivity, tumor presence, and lymph node metastases. These results suggest that plasma miR‐210 may be used to predict and perhaps monitor response to therapies that contain trastuzumab. Cancer 2011;. © 2011 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Self-citationChen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J., Zhang, Y., Chen, J., Guo, X., et al. (2008) · Cell Research · doi:10.1038/cr.2008.282 · Cited by 4,560
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Lawrie, C. H., Gal, S., Dunlop, H. M., Pushkaran, B., Liggins, A. P., Pulford, K., Banham, A. H., Pezzella, F., Boultwood, J., Wainscoat, J. S., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07077.x · Cited by 1,735
MicroRNAs in body fluids—the mix of hormones and biomarkers
Cortez, M. A., Bueso-Ramos, C., Ferdin, J., Lopez-Berestein, G., Sood, A. K., & Calin, G. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.76 · Cited by 1,465
Self-citationBuzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Self-citationMeng, F., Henson, R., Lang, M., Wehbe, H., Maheshwari, S., Mendell, J. T., Jiang, J., Schmittgen, T. D., & Patel, T. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.057 · Cited by 984
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Cited by
Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis
Zhou, W., Fong, M. Y., Min, Y., Somlo, G., Liu, L., Palomares, M. R., Yu, Y., Chow, A., O’Connor, S. T. F., Chin, A. R., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.007 · Cited by 1,476
Clinical relevance of circulating cell-free microRNAs in cancer
Schwarzenbach, H., Nishida, N., Calin, G. A., & Pantel, K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.5 · Cited by 969
Self-citationKosaka, N., Iguchi, H., Hagiwara, K., Yoshioka, Y., Takeshita, F., & Ochiya, T. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.446831 · Cited by 771
MicroRNA-Based Diagnosis and Therapy
Ho, P. T. B., Clark, I. M., & Le, L. T. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137167 · Cited by 630
Novel combination of serum microRNA for detecting breast cancer in the early stage
Shimomura, A., Shiino, S., Kawauchi, J., Takizawa, S., Sakamoto, H., Matsuzaki, J., Ono, M., Takeshita, F., Niida, S., Shimizu, C., et al. (2016) · Cancer Science · doi:10.1111/cas.12880 · Cited by 357
Metadata
- Authors
- Jung, E., Santarpia, L., Kim, J., Esteva, F. J., Moretti, E., Buzdar, A. U., Di Leo, A., Le, X., Bast, R. C., Park, S., Pusztai, L., & Calin, G. A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-10-05
- Volume
- 118
- Issue
- 10
- Pages
- 2603-2614
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1482814115
- Cited by
- 292
- References
- 36
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. https://app.cochat.ai/papers/10.1002/cncr.26565
- The paper
- Jung, E., Santarpia, L., Kim, J., Esteva, F. J., Moretti, E., Buzdar, A. U., Di Leo, A., Le, X., Bast, R. C., Park, S., Pusztai, L., & Calin, G. A. (2012). Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. https://doi.org/10.1002/cncr.26565
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
